clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Liu WZ et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10102964
Huang J and Hunt RH Clarithromycin-based triple therapies. 1999 Aliment. Pharmacol. Ther. pmid:10102978
Kohyama T et al. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. 1999 Antimicrob. Agents Chemother. pmid:10103198
Dempsey CL et al. Drug usage evaluation: clarithromycin as sequential therapy. 1993 Hosp Formul pmid:10130382
Craig AM et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. 1996 Pharmacoeconomics pmid:10160472
Gimenez Garcia R et al. Fish tank granuloma: response to treatment with clarithromycin. 1999 J Eur Acad Dermatol Venereol pmid:10188167
Fournier S et al. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. 1999 Eur. J. Clin. Microbiol. Infect. Dis. pmid:10192709
Gómez-Gil E et al. Clarithromycin-induced acute psychoses in peptic ulcer disease. 1999 Eur. J. Clin. Microbiol. Infect. Dis. pmid:10192720
Rosário M et al. [Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population]. 1998 Acta Med Port pmid:10192979
Lee CK et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. 1999 Vaccine pmid:10195786
Verbanck JJ et al. Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. 1999 Jan-Feb Perit Dial Int pmid:10201350
Sonnenberg A et al. The effect of antibiotic therapy on bleeding from duodenal ulcer. 1999 Am. J. Gastroenterol. pmid:10201462
Smoot DT et al. Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10201463
Laine L et al. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. 1999 Am. J. Gastroenterol. pmid:10201465
Zhou Q et al. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. 1999 Eur. J. Clin. Pharmacol. pmid:10206083
Miwa H et al. Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. 1999 J. Gastroenterol. Hepatol. pmid:10207779
Henry DC et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. 1999 Clin Ther pmid:10211537
McConnell SA and Amsden GW Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. 1999 Pharmacotherapy pmid:10212011
Dubois J and St-Pierre C In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. 1999 Diagn. Microbiol. Infect. Dis. pmid:10212753
Clifford K et al. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. 1999 Ann. Otol. Rhinol. Laryngol. pmid:10214783
Kashimura H et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10215732
Lee JM et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. 1999 Aliment. Pharmacol. Ther. pmid:10215733
Neville PM et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. 1999 Aliment. Pharmacol. Ther. pmid:10215734
Hoffman JS et al. Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. 1999 Aliment. Pharmacol. Ther. pmid:10215735
Abbott GW et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. 1999 Cell pmid:10219239
van der Hulst RW et al. [Treatment of Helicobacter pylori infections]. 1999 Ned Tijdschr Geneeskd pmid:10221109
Khan AA et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. 1999 Int. J. Antimicrob. Agents pmid:10221415
Sato K and Tomioka H Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. 1999 J. Antimicrob. Chemother. pmid:10223590
Garey KW et al. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. 1999 Antimicrob. Agents Chemother. pmid:10223928
Fish DN and Abraham E Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. 1999 Antimicrob. Agents Chemother. pmid:10223952
Bergman KL et al. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. 1999 Antimicrob. Agents Chemother. pmid:10223956
Gisbert JP et al. [Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments]. 1999 Med Clin (Barc) pmid:10227015
Gisbert JP [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. 1999 Rev Esp Enferm Dig pmid:10231305
Goddard AF et al. Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. 1999 Aliment. Pharmacol. Ther. pmid:10233187
Pilotto A et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10233191
Hayashi Y et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. 1999 Pacing Clin Electrophysiol pmid:10234723
Vakil N and Cutler A Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10235192
Woods GL et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. 1999 J. Clin. Microbiol. pmid:10325306
Warheker PT et al. Successful treatment of saccular endophthalmitis with clarithromycin. 1998 Eye (Lond) pmid:10326009
Carbon C and Poole MD The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. 1999 J Chemother pmid:10326741
Le Gars L et al. Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. 1999 J. Rheumatol. pmid:10332992
Bocheńska-Marciniak M et al. [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. 1998 Pol. Arch. Med. Wewn. pmid:10335027
Champney WS and Tober CL Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. 1999 Curr. Microbiol. pmid:10341075
Nitu IC et al. Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. 1999 Clin Lab Haematol pmid:10342075
Abdul Aal GM et al. Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. 1999 Digestion pmid:10343145
Dajani AI et al. One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. 1999 Digestion pmid:10343146
Sonnenberg A et al. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. 1999 Am J Manag Care pmid:10345967
Champney WS and Tober CL Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. 1999 Antimicrob. Agents Chemother. pmid:10348746
Debets-Ossenkopp YJ et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. 1999 J. Antimicrob. Chemother. pmid:10350380
Son SW et al. The response of rosacea to eradication of Helicobacter pylori. 1999 Br. J. Dermatol. pmid:10354058